Clinical trial
Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia Due to Enterobacteriaceae and Pseudomonas Aeruginosa in Hemato-oncological Patients With Severe Neutropenia and Fever: Non-inferiority Study
NCT06422533 is registered in ClinicalTrials.gov with Instituto Nacional de Cancerologia de Mexico as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia Due to Enterobacteriaceae and Pseudomonas Aeruginosa in Hemato-oncological Patients With Severe Neutropenia and Fever: Non-inferiority Study
- Lead sponsor
- Instituto Nacional de Cancerologia de Mexico
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- November 7, 2023
- Completion date
- August 30, 2025
- Enrollment
- 226 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.